Top 2 Health Care Stocks That May Collapse This Quarter
Top 2 Health Care Stocks That May Collapse This Quarter
As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年9月9日，医疗保健行业的两只股票可能会向将动量视为交易决策关键标准的投资者发出真正的警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
RSI是一个动量指标，它比较股票在价格上涨的日子里的走强与价格下跌的日子的走强。与股票的价格走势相比，它可以让交易者更好地了解股票在短期内的表现。根据Benzinga Pro的数据，当相对强弱指数高于70时，资产通常被视为超买。
Here's the latest list of major overbought players in this sector.
以下是该行业主要超买参与者的最新名单。
Terns Pharmaceuticals Inc (NASDAQ:TERN)
特恩斯制药公司（纳斯达克股票代码：TERN）
- On Sept. 9, Terns Pharmaceuticals announced a top-line data from its Phase 1 randomized, double-blind, placebo-controlled single and multiple-ascending dose trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TERN-601 dosed once-daily in healthy adults with obesity or overweight.. The company's stock gained around 19% over the past month and has a 52-week high of $10.03.
- RSI Value: 73.09
- TERN Price Action: Shares of Terns Pharmaceuticals gained 4.7% to close at $7.81 on Friday.
- 9 月 9 日，Terns Pharmicals 公布了其 1 期随机、双盲、安慰剂对照的单剂量和多递增剂量试验的主要数据，该试验旨在评估肥胖或超重健康成年人每天给药一次 TERN-601 的安全性、耐受性、药代动力学和药效学。该公司的股票在过去一个月中上涨了约19％，创下52周高点10.03美元。
- RSI 值：73.09
- TERN价格走势：周五，Terns Pharmicals的股价上涨4.7％，收于7.81美元。
Immunovant Inc (NASDAQ:IMVT)
Immunovant Inc（纳斯达克股票代码：IMVT）
- On Sept. 9, Immunovant reported positive results from the Phase 2a trial of batoclimab in Graves' Disease. "We are thrilled to share these updates today which we believe validate a large and important degree of unmet medical need in patients uncontrolled on ATDs and which we believe demonstrate strong response rates in this same population," said Pete Salzmann, M.D., chief executive officer of Immunovant. The company's stock gained around 17% over the past month and has a 52-week high of $45.58.
- RSI Value: 72.34
- IMVT Price Action: Shares of Immunovant surged 1.2% to close at $34.03 on Friday.
- 9月9日，Immunovant报告了巴托克利单抗治疗格雷夫斯病的2a期试验的阳性结果。Immunovant首席执行官Pete Salzmann万.D. 表示：“我们很高兴今天分享这些最新消息，我们认为这些更新证实了ATD得不到控制的患者在很大程度上未得到满足的医疗需求，而且我们认为这些更新在同一人群中也显示出很强的反应率。”该公司的股票在过去一个月中上涨了约17％，创下52周高点45.58美元。
- RSI 值：72.34
- iMVT价格走势：周五，Immunovant的股价上涨了1.2％，收于34.03美元。
Read More:
阅读更多：
- S&P 500 Records Largest Weekly Decline Since March 2023 As Nvidia, Google Tumble: Fear & Greed Index Moves To 'Fear' Zone
- 随着英伟达和谷歌的暴跌，标普500指数创下自2023年3月以来的最大单周跌幅：恐惧与贪婪指数移至 “恐惧” 区域